Buy Eikon Therapeutics stock | $EIKN Share Price

13:30

15:10

16:45

18:25

20:00

About Eikon Therapeutics

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Ticker

$EIKN

Sector

Health

Primary listing

NASDAQ

Employees

384

Headquarters

Millbrae, United States

Website

eikontx.com

EIKN Metrics

BasicAdvanced

$539m

-$115.29

What the Analysts think about EIKN

Analyst ratings (Buy, Hold, Sell) for Eikon Therapeutics stock.

Bulls say / Bears say

Eikon raised $381.2 million in an upsized U.S. IPO in February 2026, significantly strengthening its balance sheet to fund ongoing clinical programs.

The company completed enrollment for its TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 non-small cell lung cancer, with a comprehensive data set expected in the second half of 2026.

Eikon started a Phase 1/2 trial for its WRN helicase inhibitor EIK1005 in malignant disease and achieved first-patient dosing of its CNS-penetrant PARP1 inhibitor EIK1004, expanding its pipeline.

Eikon’s net loss widened 37% year-over-year to $333.6 million in fiscal 2025, highlighting substantial cash burn and the likelihood of needing to raise additional capital in the future.

Shares opened 5.3% below the IPO price, giving the company a market value of about $860.3 million, suggesting weaker investor appetite than expected.

With the exception of EIK1001, most of Eikon’s pipeline is still in early-stage clinical trials, increasing the risk of binary outcomes for its candidates.

Data summarised monthly by Lightyear AI. Last updated on 17 Apr 2026.

EIKN Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

EIKN Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EIKN

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Eikon Therapeutics stock?

Eikon Therapeutics (EIKN) has a market cap of $539M as of May 10, 2026.

What is the P/E ratio for Eikon Therapeutics stock?

The price to earnings (P/E) ratio for Eikon Therapeutics (EIKN) stock is 0 as of May 10, 2026.

Does Eikon Therapeutics stock pay dividends?

No, Eikon Therapeutics (EIKN) stock does not pay dividends to its shareholders as of May 10, 2026.

When is the next Eikon Therapeutics dividend payment date?

Eikon Therapeutics (EIKN) stock does not pay dividends to its shareholders.

What is the beta indicator for Eikon Therapeutics?

Eikon Therapeutics (EIKN) does not currently have a Beta indicator.

Bulls say / Bears say

Eikon raised $381.2 million in an upsized U.S. IPO in February 2026, significantly strengthening its balance sheet to fund ongoing clinical programs.

The company completed enrollment for its TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 non-small cell lung cancer, with a comprehensive data set expected in the second half of 2026.

Eikon started a Phase 1/2 trial for its WRN helicase inhibitor EIK1005 in malignant disease and achieved first-patient dosing of its CNS-penetrant PARP1 inhibitor EIK1004, expanding its pipeline.

Eikon’s net loss widened 37% year-over-year to $333.6 million in fiscal 2025, highlighting substantial cash burn and the likelihood of needing to raise additional capital in the future.

Shares opened 5.3% below the IPO price, giving the company a market value of about $860.3 million, suggesting weaker investor appetite than expected.

With the exception of EIK1001, most of Eikon’s pipeline is still in early-stage clinical trials, increasing the risk of binary outcomes for its candidates.

Data summarised monthly by Lightyear AI. Last updated on 17 Apr 2026.

About Eikon Therapeutics

Ticker

Employees

EIKN Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about EIKN

Analyst Ratings

Bulls say / Bears say

EIKN Financial Performance

Income Statement

EIKN Earnings Performance

Earnings per share (EPS)

Buy $EIKN

Upcoming events

No upcoming events

What’s the current market cap for Eikon Therapeutics stock?

What is the P/E ratio for Eikon Therapeutics stock?

Does Eikon Therapeutics stock pay dividends?

When is the next Eikon Therapeutics dividend payment date?

What is the beta indicator for Eikon Therapeutics?

Lightyear

Legal

Work with us

Bulls say / Bears say

Eikon Therapeutics/$EIKN

About Eikon Therapeutics

Ticker

Employees

EIKN Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about EIKN

Analyst Ratings

Bulls say / Bears say

EIKN Financial Performance

Income Statement

EIKN Earnings Performance

Earnings per share (EPS)

Buy $EIKN

Upcoming events

No upcoming events

What’s the current market cap for Eikon Therapeutics stock?

What is the P/E ratio for Eikon Therapeutics stock?

Does Eikon Therapeutics stock pay dividends?

When is the next Eikon Therapeutics dividend payment date?

What is the beta indicator for Eikon Therapeutics?

Bulls say / Bears say